JPMorgan Chase & Co. Has $2.33 Million Stock Holdings in Ventyx Biosciences, Inc. $VTYX

JPMorgan Chase & Co. lifted its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 63.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 748,088 shares of the company’s stock after acquiring an additional 290,169 shares during the period. JPMorgan Chase & Co. owned approximately 1.05% of Ventyx Biosciences worth $2,327,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of VTYX. Hudson Bay Capital Management LP acquired a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at approximately $34,000. Engineers Gate Manager LP bought a new stake in Ventyx Biosciences during the 2nd quarter worth approximately $42,000. Persistent Asset Partners Ltd bought a new stake in Ventyx Biosciences during the 3rd quarter worth approximately $51,000. Jump Financial LLC bought a new stake in Ventyx Biosciences during the 2nd quarter worth approximately $53,000. Finally, Jane Street Group LLC bought a new stake in Ventyx Biosciences during the 1st quarter worth approximately $56,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Ventyx Biosciences Price Performance

Shares of VTYX opened at $14.00 on Tuesday. The stock has a market capitalization of $1.00 billion, a P/E ratio of -9.33 and a beta of 1.26. Ventyx Biosciences, Inc. has a twelve month low of $0.78 and a twelve month high of $25.00. The company has a 50 day moving average of $13.98 and a 200-day moving average of $10.20.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Oppenheimer cut Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 8th. UBS Group reissued a “neutral” rating and set a $14.00 target price (down from $20.00) on shares of Ventyx Biosciences in a research note on Thursday, January 8th. HC Wainwright cut Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 target price for the company. in a research note on Thursday, January 8th. Lifesci Capital reaffirmed a “market perform” rating and set a $14.00 price target on shares of Ventyx Biosciences in a research note on Thursday, January 8th. Finally, Canaccord Genuity Group cut shares of Ventyx Biosciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $16.00 to $14.00 in a research note on Thursday, January 8th. Eight research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $14.00.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.